A new report by DART forecasts the world cell-based assay market will reach $6.9bn in 2020. That revenue prediction and others appear in Cell-Based Assays World Industry and Market Prospects 2016-2026: Products, Services, Drug Discovery, ADME, Basic Research, Organoids, Embryonic Stem Cells (ESCs), Induced Pluripotent Stem Cells (iPSCs), High-Throughput Screening (HTS) published in August 2016. DART is a business information publisher and consultancy in London, UK.
A new report by DART forecasts the overall world market for treating age-related macular degeneration (AMD or ARMD), diabetic retinopathy (DR) and other disorders of the retina will reach $17.38bn in 2020. That revenue forecast and others appear in Retinal Diseases: Wet and Dry AMD, Diabetic Retinopathy Market 2016-2026: Aflibercept, Ranibizumab, Bevacizumab, Verteporfin, Ocriplasmin, Anti-VEGF, Anti-PDGF, published in July 2016.
Studies Published over the Last 10 Years Report Reductions in Cervical Pre-cancers and Other HPV-related Diseases
KENILWORTH, N.J. Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that in a systematic review conducted of the global impact and effectiveness of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant], substantial reductions were observed in HPV 6/11/16/18-related infection, genital warts, Pap abnormalities and cervical pre-cancers. This evaluation of 58 effectiveness and impact studies published during the past 10 years examined the use of GARDASIL in routine vaccination programs in Australia, Europe, North America and New Zealand, and will be presented for the first time during an oral session at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) congress in Austria. A paper detailing this review was also published online on June 14 in the journal Clinical Infectious Diseases (CID).
Humanwell Healthcare, China’s biggest pharmaceutical manufacturing company, has invested two billion Birr for the construction of its plant in Ethiopia – its second investment destination on the continent, after Mali, in West Africa.
Mebratu Melese (PhD), state minister for Industry, accompanied Xurong Li, the company’s operation management department’s deputy head, as well as zonal and wereda level officials, two weeks before laying the building’s cornerstone.
- Progress on biosimilar pipeline paves way for five planned launches by 2020
- Sandoz now plans a total of 11 biosimilar filings by end 2017 (EU and US) and has already delivered on six
- Investments of more than USD 1 billion in state of-the-art biomanufacturing facilities, backed by industry-leading capabilities as part of Novartis, positions Sandoz to deliver biosimilars at unprecedented scale